These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 24240114)

  • 1. Neutrophils promote the malignant glioma phenotype through S100A4.
    Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
    Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
    Liang J; Piao Y; Henry V; Tiao N; de Groot JF
    Oncotarget; 2015 Oct; 6(31):31479-92. PubMed ID: 26362401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
    DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
    Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
    de Groot J; Liang J; Kong LY; Wei J; Piao Y; Fuller G; Qiao W; Heimberger AB
    Oncotarget; 2012 Sep; 3(9):1036-48. PubMed ID: 23013619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma.
    Chow KH; Park HJ; George J; Yamamoto K; Gallup AD; Graber JH; Chen Y; Jiang W; Steindler DA; Neilson EG; Kim BYS; Yun K
    Cancer Res; 2017 Oct; 77(19):5360-5373. PubMed ID: 28807938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
    Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
    Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
    Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
    Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
    Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
    Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.